Liquid Biopsies in Follicular Thyroid Carcinomas-A Brief Report.
Marie-Louise Uhre HansenSimone Kloch BendtsenKathrine Kronberg JakobsenAne Yde SchmidtChristoffer Holst HahnChristian von BuchwaldChristian GrønhøjPublished in: Diagnostics (Basel, Switzerland) (2024)
Thyroid cancer (TC) represents a significant health burden globally, with follicular thyroid cancer (FTC) posing diagnostic challenges despite advancements. This pilot study aimed to evaluate the utility of a liquid biopsy with cell-free DNA (cfDNA) in patients with FTC. Blood samples were collected from 13 patients diagnosed with FTC, DNA extraction was performed, and cfDNA was analyzed using the Illumina's TruSight Oncology 500 High-Throughput panel. The results revealed low tumor mutational burden and minimal pathogenic variants in cfDNA, indicating challenges such as low DNA yield and poor material quality despite adequate coverage. Our findings indicate that cfDNA as an add-on diagnostic tool in patients with FTC might not be a useful supplement.
Keyphrases
- high throughput
- end stage renal disease
- circulating tumor
- newly diagnosed
- ejection fraction
- healthcare
- cell free
- single molecule
- chronic kidney disease
- public health
- ultrasound guided
- mental health
- prognostic factors
- copy number
- peritoneal dialysis
- gene expression
- dna methylation
- patient reported outcomes
- fine needle aspiration